World's highest yield aAV production technology

AAV packaging service

Need custom produced AAV? Our innovative AAV production service is 10-100 times more efficient than traditional methods and produces up to 1E+15GC/mL AAV in one single production. Get a free consultation today and improve your AAV vectors' infection efficiency while saving budget.

Begin Inquiry

Talk to Us

AAV production cost

How much does aav cost?

Standard production pricing list

Our standard AAV packaging services pricing are listed in the table below.

The following prices are based on a volume of 1ml

Target Titer* Prices Start From
1x1013 GC/ml $2,795
4x1013 GC/ml $5,850
7x1013 GC/ml $11,000
1x1014 GC/ml $13,000
2x1014 GC/ml $19,500
3x1014 GC/ml $25,950
4x1014 GC/ml $32,450
5x1014 GC/ml $39,000

*We guarantee to deliver at least the amount of virus (VG = vector genome, or vector genome copy, equivalent to GC) you ordered. All AAV vectors will be purified and ready for animal injections. Typical AAV titers range between 2-2.5e+13vg/ml.

Begin inquiry

Why Choose Boster Bio?

At Boster Bio, we offer the world’s highest yielding AAV production quality. We are able to produce highly concentrated AAVs with low vacancy capsids that maximize infection efficiency for all tissue types. Our system is 10-100 times more efficient, so you save on cost as well. Double-wins.

We are able to provide not only packaging services, but also cloning services as a CRO to outsource the entire viral portion of your project. We can cover the entire viral portion of your project, from gene synthesis, cloning to vector construction and packaging and anything else in between.

Our AAVs are Research Grade Only for use in the early stages of drug discovery R&D to test your Gene of Interest in vitro or with in vivo animal studies.

Ideal for research and pharma clients to outsource partial or total AAV production.

AAV Services Overview

Gene Synthesis

Clone Gene into the Vector

Packaging into viral vector and expanding

Quality Control

How To Order?

As easy as 1, 2, 3.

1. Arrange a meeting with our Project Concierge


2. Get a Quote


3. Place an Order


How Does It Work?

Boster Bio can offer two different AAV production systems tailored to your needs. We can accommodate for your gene of interest of up to 4.7kb in size

Triple Transfection Method

Utilizing a unique packaging mix for each different serotype, our triple transfection AAV system in HEK293 cells contain two plasmids which separate the AAV structural and replication genes until the time of viral production. This prevents the structural genes from being present in the genome of the produced virus, and increases the safety of the user by making the viruses replication incompetent. Typical turnaround time 4-6 weeks

triple_transfection_system

Baculovirus Method

Using a patented technology, we are also able to produce AAV vectors on a large scale in Sf9 cells under serum-free condition through infection with two recombinant baculoviruses, one carrying the AAV rep/cap genes, and a second carrying the gene of interest flanked by two AAV ITRs. This set up allows us to control cellular toxicity and produce huge amounts of AAV without killing the host. Typical turnaround time 6-8 weeks.

baculovirus_system

Custom & Non-Standard AAV Services

If you are looking for a custom order involving a non-standard volume, titer, purification or require a fast turnaround or delivery, please get in contact to discuss further.

Our expert team are on hand to discuss your project further and provide accurate details in regards to pricing and estimated delivery times.

Want to know more about these cool technologies or license it? Contact us today.


About Boster Bio's AAV packaging

10-100x
more efficient

High Purity
high Potency

Guaranteed
titer

Patented
technologies

Serving Science
since 1993

Begin inquiry


Applications and Guarantees

Applications

mascot-1
  • Our AAV can be used for Research to GLP and pre-GMP in vivo studies
  • We offer free cell infection validation if the AAV cargo contains a GFP or RFP under the control of a constitutive promoter
  • If you do not have “ready-to-package” AAV vectors, we can generate these.
  • Other viruses available: lentiviruses, adenoviruses, baculoviruses, HSVs.

Our QC Includes

mascot-2
  • Titer Test. This is done via qPCR with universal ITR
  • Sterility Test.
  • Infection QC. If your vector includes GFP and/or RFP under the control of a constitutive promoter (e.g., CMV, PGK, EF1α, etc.), we check whether GFP and/or RFP is expressed after packaging and infection in cells. This additional level of QC is provided free-of-charge.
  • SDS Page Gel on AAV proteins VP1, VP2 and VP3 to determine purity
  • We can also include an endotoxin assay, and/or have the final product sequence verified at an additional cost.

Guarantees

mascot-3

We guarantee titer and end applications:

  • Using AAV for GOI over-expression, we guarantee over-expression of the target gene at the mRNA level
  • Using the AAV for siRNA we guarantee knock-down of the target gene at the mRNA level

Questions to consider for AAV production

AAV's Transduction Efficiency depends capsid-receptor interaction, cellular uptake and translation. 3 key factors affect AAV transduction success: correct serotype to tissue match, high titer of capsids and high percentage of effective capsids.

Why use AAV?

Recombinant AAV (rAAV) delivers targeted specificity and low immunogenicity. Therefore it is a powerful tool for in vivo gene delivery, and as a result AAV has become the dominant form of gene therapy for genetic diseases. AAV used in the only two FDA-approved gene therapies currently available and is driving many of today’s therapeutic discoveries.

Most gene therapy vectors work by integrating their genetic material into a patient’s cells; however, rAAV-delivered genes remain in the extrachromosomal state and are not incorporated into the host genome. This is an advantage, as rAAV vectors can infect both quiescent and dividing cells and are not known to cause diseases in humans.

AAV is the most promising candidate for virus-based gene therapy as it:

  • Infects both dividing and non-dividing cells
  • Has low immunogenicity and pathogenicity
  • Can target a broad range of specific tissue type
  • Provides long-term expression in non-dividing cell

Why is High Titer important for AAV production?

In gene and cell therapeutics, the need for producing high concentrations or titers of AAV is driven by its ability to infect a cell. While an individual AAV’s ability to infect a cell is dependent on its capsid construction and the cell it is infecting, it’s efficiency can also be titer dependent. An AAV particle needs to be in contact with the cell surface in order to infect it, so in order to ensure a better infection rate we may need to increase the AAV concentration.

However not all titers are the same. The physical titer is the concentration of viral particles containing viral genomes but this may differ to the infectious titer which is the concentration of viral particles that can transduce cells. So the ratio of physical to infectious viral particles indicates the specific infectivity of AAV preparations. A further consideration also needs to be made for the ratio of full to empty capsids as the amount of genome-containing viral particles compared to the total number of capsids.

If a high level of gene expression is required, then a higher titer of AAV may need to be produced. For example, fluorescent proteins may require many viral particles to infect a cell to show visible expression of the protein.

As many AAV particles are required in order to infect a cell to produce expression, in most cases the higher the titer the better.

Why is Tropism and Serotype important for AAV production?

Differences between cell surface receptors of the AAV serotype determine its tropism but it is also believed to be affected by cellular uptake, intracellular processing, nuclear delivery of the vector genome, uncoating, and second strand DNA synthesis. After discovering that the capsid surface proteins can determine the tropism, scientists have genetically modified the viral capsid, and generated mosaic vectors to create chimeric virions by swapping domains or amino-acids between serotypes. This has allowed researchers to specifically target cells with certain serotypes to effectively transduce and express genes in a localized area. To date, a total of 11 serotypes of AAV have been described and each with its own unique traits and tropisms.

AAV serotypes

  • From serotype to tissue type:
    Serotype Tissue Tropism
    AAV1 Smooth muscle, skeletal muscle, CNS, brain, lung, retina, inner ear, pancreas, heart, liver
    AAV2 Smooth muscle, CNS, brain, liver, pancreas, kidney, retina, inner ear, testes
    AAV2.7m8 Retina, inner ear
    AAV2-retro Spinal nerves
    AAV3 Smooth muscle, liver, lung
    AAV4 CNS, retina, lung, kidney, heart
    AAV5 Smooth muscle, CNS, brain, lung, retina, heart, immune system
    AAV6 Smooth muscle, heart, lung, pancreas, adipose, liver, immune system
    AAV7 Smooth muscle, retina, CNS, brain, liver
    AAV8 Smooth muscle, CNS, brain, retina, inner ear, liver, pancreas, heart, kidney, adipose
    AAV9 Smooth muscle, skeletal muscle, lung, liver, heart, pancreas, CNS, retina, inner ear, testes, kidney, adipose
    AAVShH10 Retina
    AAVrh10 Retina, liver, brain
    AAV-DJ Liver, heart, kidney, spleen, retina
    AAV-PHP.eB CNS
    AAV10 Kidney, Uterus, heart, liver, lung, skeletal muscle
    AAV11 Kidney, spleen, stomach, heart, lung skeletal muscle
  • From tissue type to serotype to:
    Tissue Type Recommended AAV Serotype
    Smooth Muscle AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9
    Skeletal Muscle AAV1, AAV9, AAV10, AAV11
    CNS AAV1, AAV2, AAV4, AAV5, AAV7, AAV8, AAV9, AAV-PHP.eB
    Brain AAV1, AAV2, AAV5, AAV7, AAV8
    Retina AAV1, AAV2, AAV2.7m8, AAV4, AAV5, AAV7, AAV8, AAV9, AAVShH10, AAVrh10, AAV-DJ
    Inner Ear AAV1, AAV2, AAV6.2, AAV8, AAV9, AAV2.7m8
    Lung AAV1, AAV3, AAV4, AAV5, AAV6, AAV6.2, AAV9, AAV10, AAV11
    Liver AAV1, AAV2, AAV3, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh10, AAV-DJ, AAV10
    Pancreas AAV1, AAV2, AAV6, AAV8, AAV9
    Heart AAV1, AAV4, AAV5, AAV6, AAV8, AAV9, AAV-DJ, AAV10, AAV11
    Kidney AAV2, AAV4, AAV8, AAV9, AAV-DJ, AAV10, AAV11
    Adipose AAV6, AAV8, AAV9
    Testes AAV2, AAV9
    Spleen AAV-DJ, AAV11
    Spinal Nerves AAV2-retro


We can also offer other serotypes not listed above. Please contact us for more information

Contact Us

Example Data

egfp-expression-and-b-tubulin

Left: EGFP expression (Green) in lumbar neuronal cells 4 weeks after intrathecal injection of AAV-EGFP Serotype 9 (Cat. # iAAV01509) into mice.

Right: Overlay with β-tubulin (red) and DAPI (blue).


Image courtesy of Dr. Douglas Lopes, King’s College London.
immunohistochemical-staining

Immunohistochemical staining reveals robust NeuN gene disruption in the spinal cord.


Ref: https://www.nature.com/articles/s41434-021-00224-2

Sample AAV Packaging Report

FAQs

Still got questions about our AAV packaging services?

We offer AAV packaging services for small-scale experimentation, all the way through to large scale commercial production. Please refer to the list of standard products for more information, or get in touch with our team to discuss custom orders.

The turnaround time for AAV packaging services depends on your specific order details. In general this usually takes 4-6 weeks for the Baculovirus Systema and 6-8 weeks for the Triple Transfection System. To find out more about expected turnaround times before you make an order, please get in contact with our team via our Project Concierge.

Choosing the right AAV Packaging Service will depend on your project requirements. The Triple Transfection system is suitable for smaller volumes of AAV, and can be relatively cost effective. The Baculovirus system is more suitable for larger volumes of AAV, and tends to take less time. For more information on both services see How Does it Work?. You will also need to choose your serotype depending on the tissue type or tropism of your sample. Please refer to the section Choose the Right AAV Serotype which help guide you to choosing an AAV Serotype based on tissue type or tissue tropism. Finally, the best resource you can use is to engage our Project Concierge, who are happily available to help with your specific requirements.

Our AAV packaging services are suitable for a range of different experimentation requirements. Due to its targeted specificity and low immunogenicity the predominant use of AAV technology is in gene therapy applications. AAV can be used in a wide range of pre-clinical and clinical applications in multiple diseases due to its unique biological and biophysical properties. Whether that be in vitro, clinical trials or full-scale production, we can ensure the right products for you. Contact our Project Concierge to discuss your specific project requirements.

Yes. Wild type AAV lacks many proteins necessary to reproduce on its own, making it a prime candidate for gene therapy research. All of Boster’s rAAV’s are replication-defective, non-communicable and can be used in BSL1 and 2 settings. For the Triple Transfection Method we utilise a 3-plasmid co-transfection system which makes the recombinant AAV non-replicable. In the Baculovirus System, we express AAV Rep and Cap genes in trans with our Baculovirus expression system. As Baculovirus is specific to insect cells it poses no threat to mammalian cell lines, and it allows us to make AAV products without the risk of residual adenovirus contamination from helper viruses in triple transfection.

AAV’s major drawback is its very small genome size compared to other existing viral vectors. For instance, compared to adenovirus or lentivirus, AAV is 5 to 10X smaller in genome size. The smaller genome size restricts the size of the gene that can be inserted to less than 4.7 kb in length. To discuss your specific requirements please contact our Project Concierge.

In general, the titer is of more importance because it is a measurement of the number of viral particles per volume.

Purity will be a more important consideration for in vivo studies. If the virus is not pure, it could cause undesired responses to the experimental animals. Our high titer AAVs are suitable for in vivo studies.

For more information on why AAV titer is important click here.

AAVs are known to have low immunogenicity, so it should not be an issue. Compared to other viral vectors (i.e. Lentivirus, Adenovirus), AAV elicits the least amount of immune response in vivo. For more information see Why use AAV?.

Our storage solution for AAVs produced via triple transfection is PBS with 5% Glycerol, which is suitable for in vivo injection. For AAV’s produced using the Baculovirus system storage solution is 1xPBS buffer containing 0.001% pluronic F-68. AAV is stable at 4° C for short-term use and room temperature for immediate use. For long-term storage, AAV should be stored at -80° C for best quality and longevity. Although AAV is a very stable virus, multiple freeze-thaw cycles may reduce the titer of the product.

For Shipping, Ordering and Storage details please see our Sample Collection Guidelines.

If your gene of interest is smaller than 4.7 kilo base pairs (kbp), we can package it into our rAAV products. We do not package gene sequences that may be unsafe to humans or the environment, such as those that are carcinogenic and those that encode for dangerous pathogens. We can always try to package larger AAV vectors as required, however if the GOI exceeds the packaging limit, the titer will be low.

These AAV products are modifications of wild-type AAV5 and AAV8. In each product, the Phospholipase A2 domain encoded by the VP1 Cap gene has been replaced with the corresponding domain from AAV2. Functionally, the activity of this enzyme allows the virus to escape the cellular vesicle once it has been endocytosed into the target cell, therefore avoiding breakdown by lysozymes. AAV2 demonstrates some of the highest phospholipase activity, so we have integrated the AAV2 wild-type domain into our AAV5.2 and AAV8.2 products with no alteration in tropism to increase infectivity

Please request a quote from us. Our controls are produced with a titer of ~2 x 10^13 vg/mL. We can schedule ready-made controls for shipment as soon as we receive a form of payment referencing a quote number. Please contact our Project Concierge for ordering details.

Our production timeline is between 4-8 weeks for custom projects. This timeline will be lengthened if you request a more complex multi-step cloning procedure, or want us to produce your own capsid. For accurate timelines on your specific project please contact our Project Concierge.

We can make AAV to over-express any genes (wildtype, mutant or synthetic) and to silence/knockout any genes from any species if you don’t have any starting material. Our scientists are available to discuss your specific requirement and come up with the recommended AAV constructs for your specific needs. Contact our Project Concierge to discuss your specific requirements.

Initially we will need to know the following in order to send you a quote:

  1. The size of the gene you wish to package, and if gene synthesis is required.
  2. The AAV serotype you wish to package.
  3. The production scale size in vector genome (vg) equivalent to genome copy.
  4. If a pre-made control AAV is required, please include the name of the control vector, the AAV serotype, and desired volume and titer.

Please contact our Project Concierge to discuss your specific requirements and we will tailor the service to your needs.


If you accept the quote and wish to proceed with one of Boster’s AAV Packaging Services, we require the following materials:

  1. The plasmid with your target gene. 10-20uL of DNA at 0.5ug/uL. We can accept plasmids blotted onto filter paper, however this will require an extra purification step at an extra cost. If you do not have ready-made DNA we can offer a Gene Cloning Service.
  2. The text file of the DNA sequence. Files we accept include .dna, .doc, .docx, or any other plain text files. We will keep your information absolutely confidential, and its use will be limited to the project outlined in the quote, unless further requests are made from the original ordering entity.
  3. A form of payment.

We use vector genome (vg) as our unit to measure AAV production scale. This unit is similar to genome copy (gc) – it refers to the number of complete copies of the gene of interest that are present in the final suspension.

The titer (in vg/mL), or concentration, of our virus products is typically ~2 x 10^13 vg/mL. However, some genes are either toxic to cells or detrimental to AAV efficiency, and some serotypes (e.g, AAV 2, 3, 6) are low yield. In these cases, the expected titer may be lower.

Both titer and volume can be adjusted to the customer’s requirements, but the price of the product will always depend on the vector genome (vg) amount.

For more details on expected yields for your specific project, contact the Project Concierge.

Our QC details can be found here and are detailed below:

  • Titer Test. This is done via qPCR with universal ITR
  • Sterility Test.
  • Infection QC. If your vector includes GFP and/or RFP under the control of a constitutive promoter (e.g., CMV, PGK, EF1α, etc.), we check whether GFP and/or RFP is expressed after packaging and infection in cells. This additional level of QC is provided free-of-charge.
  • SDS Page Gel on AAV proteins VP1, VP2 and VP3 to determine purity
  • We can also include an endotoxin assay, and/or have the final product sequence verified at an additional cost.